Background: The role of folate, vitamin B12 and homocysteine levels in depression is not clear.Aims: To investigate cross-sectional and prospective associations between folate, B12 and homocysteine levels and late-life depression.Method: A total of 732 Korean people aged 65 years or over were evaluated at baseline. Of the 631 persons who were not depressed, 521 (83%) were followed over a period of 2–3 years and incident depression was ascertained with the Geriatric Mental State schedule. Serum folate, serum vitamin B12 and plasma homocysteine levels were assayed at both baseline and follow-up.Results: Lower levels of folate and vitamin B12 and higher homocysteine levels at baseline were associated with a higher risk of incident depression at follow-up. Incident depression was associated with a decline in vitamin B12 and an increase in homocysteine levels over the follow-up period.Conclusions: Lower folate, lower vitamin B12 and raised homocysteine levels may be risk factors for late-life depression.
1 March 2005 in Human Psychopharmacology: Clinical and Experimental
To investigate prevalence, incidence, and persistence of insomnia, and their bidirectional longitudinal associations with depression and physical disorders. A community based longitudinal study. Elders living in private households in South Korea. 1204 people ≥ 65 years of age were evaluated at baseline; 909 of them (75%) were re-interviewed after 2 years. Insomnia was defined as difficulty in initiation or maintenance of sleep > 3 nights per week over the last month. Diagnosis of depression (Geriatric Mental State) and number of physical disorders were ascertained. Sociodemographic and clinical covariates included age, gender, education, housing, past occupation, current employment, living area, life events, social deficit, physical activity, cognitive impairment, anxiety, and daily drinking. Of those (27%) with insomnia at baseline, 40% had insomnia at follow-up. Of those without insomnia at baseline, 23% had insomnia at follow-up. Baseline depression was significantly associated with prevalence and incidence of insomnia. Baseline number of physical disorders was significantly associated with prevalence, incidence, and persistence of insomnia. Baseline insomnia was independently associated with incident depression and an increase in reported physical disorders. Insomnia was common and often persistent in this population. Insomnia was closely and reciprocally related to depression and physical disorders.
13 February 2008 in Psychiatry and Clinical Neurosciences
Aims: The purpose of the present paper was to evaluate the effectiveness of mirtazapine orally disintegrating tablets for nausea and sleep disturbance, which are common and distressing symptoms of cancer.Methods: This was a 4‐week, prospective, open‐labeled study of cancer patients. Assessments were performed at baseline and on days 1, 3, 5, 7, 14, and 28. Primary outcome measures were the Clinical Global Impression scale for nausea/vomiting and the Chonnam National University Hospital–Leeds Sleep Evaluation Questionnaire (C‐LSEQ) including total amount of night sleep time. The secondary outcome measures consisted of pain items in the 36‐item Short Form Health Survey, the Montgomery–Asberg Depression Rating Scale (MADRS), and the EuroQoL (EQ)‐5D. Forty‐two cancer patients were enrolled.Results: Those with nausea (n = 28) improved significantly from day 1. The total night sleep time and each item on the C‐LSEQ improved from days 1–5. The scores on the MADRS and the depression/anxiety dimension and visual analog scale of EQ‐5D improved significantly from the first week. Pain measures also improved from day 1. Exacerbation of sleepiness developed in approximately one‐third of subjects during the initial few days, but disappeared gradually.Conclusion: In the present study mirtazapine rapidly improved nausea, sleep disturbance, pain and quality of life, as well as depression in cancer patients. Mirtazapine may be an effective treatment option in managing cancer patients with multiple distressing symptoms, including nausea and sleep disturbance.